Mayne Pharma Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$8.2M
Doctors Paid
18,503
Transactions
93,777
2022 Total
$715,061
Payment Breakdown by Category
Research$5.8M (70.7%)
Food & Beverage$1.6M (19.8%)
Consulting$357,949 (4.4%)
Travel$72,519 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.8M | 165 | 70.7% |
| Food and Beverage | $1.6M | 93,177 | 19.8% |
| Consulting Fee | $357,949 | 70 | 4.4% |
| Honoraria | $341,459 | 175 | 4.2% |
| Travel and Lodging | $72,519 | 141 | 0.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,325 | 9 | 0.0% |
| Gift | $1,075 | 1 | 0.0% |
| Education | $95.00 | 38 | 0.0% |
| Entertainment | $29.20 | 1 | 0.0% |
Payments by Type
Research
$5.8M
165 transactions
General
$2.4M
93,612 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Ivermectin Lotion Clinical Endpoint Study | $1.1M | 0 | 10 |
| A Comparative Bioavailability Study Comparing SUBA-itraconazole Capsules Mayne Pharma, Inc. Co-Administered with Omeprazole Delayed-Release Capsules Sandoz Inc. in Healthy Adult Subjects | $631,000 | 0 | 9 |
| ENDEMIC MYCOSES STUDY | $556,745 | 0 | 17 |
| An Open-Label, Randomized, Two-Treatment, Two-Sequence, Two-Period, Cross-over, Multiple-Dose, Steady-State, Oral Bioequivalence Study of SUBA-Itraconazole Capsules 65 mg 2 X 65 mg BID Test and Sporanox Itraconazole Capsules 100 mg 2 X 100 mg BID Reference in Healthy, Adult, Human Subjects under Fed Conditions | $545,492 | 0 | 5 |
| An Open-Label, Randomized, Two-Treatment, Two-Sequence, Two-Period, Cross-over, Multiple-Dose, Steady-State, Food Effect Study of SUBA-Itraconazole Capsules 65 mg 2 X 65 mg BID Test in Healthy, Adult, Human Subjects under Fasting and Fed Conditions | $545,492 | 0 | 7 |
| Permethrin Bioequivalence | $388,911 | 0 | 4 |
| SUBA-INTRACONAZOLE VERSUS CONVENTIONAL ITRACONAZOLE IN THE TREATMENT OF ENDEMIC MYCOSES: A MULTI-CENTER, OPEN-LABEL, RANDOMIZED COMPARATIVE TRIAL | $304,544 | 0 | 12 |
| SUBA-Intraconazole VS Conventional Itraconazole in the Treatment of Endemic Mycoses | $229,200 | 0 | 1 |
| An Open-Label, Randomized, 2- Treatment, 2-Sequence, 2-Period, Crossover, MD, Oral BE Study of Lozanoc Itraconazole Capsules 65 mg 2 X 65 mg Test and Sporanox Itraconazole Capsules 100 mg 2 X 100 mg Reference Administered 3 Times Daily 8 Hours apart from Days 1-3 and Once a Day 2 X 65 mg of Test2 X 100 mg of Reference on Day 4 in Healthy, dult, Human Subjects, under Fed Conditions | $170,478 | 0 | 3 |
| SORILUX PEDIATRIC | $128,191 | 0 | 15 |
| SORILUX5FUCRYO COMBINATION THERAPY | $65,000 | 0 | 1 |
| A multicenter, open-label, Phase 1 study of the safety, tolerability, systemic exposure, pharmacodynamics, and treatment effect of calcipotriene foam, 0.005 in pediatric subjects ages 2 to 11 years with plaque psoriasis | $29,963 | 0 | 7 |
| OPEN-LABEL RANDOMIZED CLINICAL TRIAL OF DOXYCYCLINE PEP TO REDUCE BACTERIAL STIS AMONG MSM LIVING WITH HIV AND HIV-UNINFECTED MSM OR PREP. | $28,230 | 0 | 1 |
| DOXY PEP GRANT | $28,230 | 0 | 1 |
| Lamellar Ichthyosis Phase II Study | $15,000 | 4 | 4 |
| MSG-15 | $13,550 | 0 | 2 |
| CASE STUDY OF COMBO THERAPY LEXETTESORILUX FOR TREATMENT OF SCALP PSORIASISSEBOPSORIASIS | $7,707 | 1 | 2 |
| SORILUX ADOLESCENT | $7,235 | 0 | 6 |
| LAMELLAR ICHTHYOSIS PHASE II | $5,625 | 2 | 2 |
| Efficacy of tazarotene foam vs vehicle in treatment of facial photodamage | $5,376 | 1 | 1 |
| Use of Fabior for keratoderma for psorisis | $3,226 | 1 | 1 |
| Single point, randomized, evaluator blinded within subject single center evaluation of the vasoconstrictive properties of halobetasol proprionate foam 0.05 in healthy adults | $2,748 | 1 | 3 |
| Phase IIb open label trial of SUBA-itraconazole in subjects with basal cell carcinoma nevus syndrome BCCNS | $2,600 | 0 | 1 |
| SUBA-INTRACONAZOLE VERSUS CONVENTIONAL ITRACONAZOLE IN THE TREAMENT OF EDEMIC MYCOSES: A MULTI-CENTER, OPEN-LABEL, TADOMIZED COMAPARATIVE TRIAL. | $1,600 | 0 | 1 |
| A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005, Applied Under Maximal-Use Conditions in Adolescent subjects Ages 12 to 16 Years with Plaque Psoriasis | $1,000 | 0 | 1 |
| AN OPEN LABLE EVALUATION OF THE ADRENAL SUPPRESSION POTENTIAL AND PHARMACOKINETIC PROPERTIES OF TWICE DAILY OF HALOBETASOL PROPIONATE FOAM, 0.05% IN SUBJECTS 12 TO LESS THAN 18 YEARS OF AGE WITH PLAQUE PSORIASIS RECEIVING TWO WEEKS OF TREATMENT | $253.80 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Jay Cohen, Md, MD | Obstetrics & Gynecology | Plantation, FL | $3,651 | $0 |
| Dr. Kenneth Dawes, M.d, M.D | Dermatology | Indianapolis, IN | $3,622 | $0 |
| Dr. Martin Menter, Md, MD | Dermatology | Dallas, TX | $3,366 | $0 |
| Dr. Suzanne Fenske, M.d, M.D | Obstetrics & Gynecology | New York, NY | $3,357 | $0 |
| Thomas Kimble, Md, MD | Obstetrics & Gynecology | Norfolk, VA | $3,120 | $0 |
| George Thompson Iii, Md, MD | Internal Medicine | Sacramento, CA | $2,932 | $0 |
| Moise Levy, Md, MD | Dermatology | Austin, TX | $2,925 | $0 |
| Dr. Angela Moore, Md, Pa, MD, PA | Dermatology | Arlington, TX | $2,882 | $0 |
| Dr. Michelle Barron, M.d, M.D | Infectious Disease | Denver, CO | $2,757 | $0 |
| David Altman, Md, MD | Dermatology | Warren, MI | $2,729 | $0 |
| Dr. Jeffrey Sugarman, M.d., Ph.d, M.D., PH.D | Pediatric Dermatology | Santa Rosa, CA | $2,700 | $0 |
| Mary Moore, M.d, M.D | Dermatology | Missouri City, TX | $2,651 | $0 |
| Stephen Hess, Md, MD | Dermatology | Philadelphia, PA | $2,641 | $0 |
| Vincent Valentine, Md, MD | Pulmonary Disease | Baton Rouge, LA | $2,638 | $0 |
| Angel Puryear, M.d, M.D | Dermatology | Missouri City, TX | $2,594 | $0 |
| Stephanie Cotell, M.d, M.D | Dermatology | Gahanna, OH | $2,588 | $0 |
| Jordan Vaughan, Apn, APN | Women's Health | Nashville, TN | $2,540 | $0 |
| Mr. Tony Hodges, M.d, M.D | Pulmonary Disease | Phoenix, AZ | $2,510 | $0 |
| Josep Genebriera De Lamo, M.d, M.D | Student in an Organized Health Care Education/Training Program | Jacksonville, FL | $2,495 | $0 |
| Dr. Todd Moore, Md, Pa, MD, PA | Clinical & Laboratory Dermatological Immunology | Arlington, TX | $2,302 | $0 |
| Dr. James Childs, M.d, M.D | Dermatology | College Station, TX | $2,279 | $0 |
| Dr. Syed Ali, M.d, M.D | Dermatology | West Hills, CA | $2,237 | $0 |
| Edward Garrity, Md, MD | Critical Care Medicine | Burr Ridge, IL | $2,164 | $0 |
| Dr. Lisa Hitchins, M.d, M.D | Dermatology | Cypress, TX | $2,152 | $0 |
| William Cothern, Do, DO | Dermatology | Fort Worth, TX | $2,080 | $0 |
Ad
Top Products
- TOLSURA $1.2M
- DORYX $1.0M
Associated Products (10)
- TOLSURA $1.2M
- DORYX $1.0M
- ELIMITE $388,911
- SORILUX $356,083
- TRIMETHOPRIM $99,000
- FABIOR $61,022
- NORTRIPTYLINE HYDROCHLORIDE 10MG $59,244
- LEXETTE $29,584
- TOLSURA - 60 CAPSULE $12,500
- MICROGESTIN $11,775
Payment Categories
- Food & Beverage $1.6M
- Consulting $357,949
- Travel & Lodging $72,519
- Research $5.8M
About Mayne Pharma Inc.
Mayne Pharma Inc. has made $8.2M in payments to 18,503 healthcare providers, recorded across 93,777 transactions in the CMS Open Payments database. In 2022, the company paid $715,061. The top product by payment volume is TOLSURA ($1.2M).
Payments were distributed across 162 medical specialties. The top specialty by payment amount is Dermatology ($854,626 to 3,584 doctors).
Payment categories include: Food & Beverage ($1.6M), Consulting ($357,949), Research ($5.8M), Travel & Lodging ($72,519).
Mayne Pharma Inc. is associated with 10 products in the CMS Open Payments database, including TOLSURA, DORYX, and ELIMITE.